Policlinico of Milan

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

Retrieved on: 
Friday, May 12, 2023
Ludwig Maximilian University of Munich, Abstract, Policlinico of Milan, Radiation, Hair loss, Patient satisfaction, DRS, Research, Irritation, Prostate, Congress Center, Doctor of Philosophy, Sale, Cancer, Radiation therapy, Assuta Medical Center, MRI, Hospital, Magnetic resonance imaging, DWI, Sarcoma, Physician, Risk, Patient, Messe, Annual general meeting, Nausea, Liver, Toxic encephalopathy, Oncology, European Society for Medical Oncology, FDA, Fatigue, RTT, Medical imaging, Pharmaceutical industry, MD

DENVER, May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.

Key Points: 
  • This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.
  • ViewRay will host a lunch symposium on Saturday, May 13, from 13:00 – 14:00 CEST at the Messe Congress Center, Lehar 1-2-3 titled, "MRIdian A3i™*: Transforming MR-guided Radiation Therapy."
  • MRIdian A3i* introduces the 4th generation of real-time tissue tracking with automatic beam gating, now with multiplanar tracking and gating.
  • Radiation treatments may cause side effects that can vary depending on the part of the body being treated.

Pilot Kidney Exchange Transplant Program Launched Between US, Italy

Retrieved on: 
Friday, September 9, 2022
General Health, Surgery, Other Health, Hospitals, Health, Partnership, CNT, Patient, University, Kidney failure, Ministry, CEO, Technology, Transplant, Safety, Program, Research, Istituto Superiore di Sanità, CIR, United Arab Emirates, MOH, Ministry of Health (Spain), Insurance, National Health Service, Doctor of Philosophy, Kidney, Tissue, APKD, Cardillo, Nobel Prize controversies, Education, Multimedia, Hospital, MD, Antibody, Population, ISS, Emirates, Rees, Policlinico of Milan, Kidney transplantation, Woman, Pharmaceutical industry, Dentistry, EU

The Alliance for Paired Kidney Donation (APKD) , an Ohio-based, non-profit organization managing an international kidney exchange registry, today announces the launch of a pilot kidney exchange transplant program between the United States and Italy.

Key Points: 
  • The Alliance for Paired Kidney Donation (APKD) , an Ohio-based, non-profit organization managing an international kidney exchange registry, today announces the launch of a pilot kidney exchange transplant program between the United States and Italy.
  • The new US-Italy program concerns kidney exchange transplantation, in which incompatible living donor and recipient pairs are matched with other incompatible pairs for kidney transplants.
  • Today in the U.S., about 20% of the 6,000 living donor kidney transplants performed are achieved through kidney exchange.
  • This kidney exchange program with the U.S. is the second international exchange program launched by Italy.

Newronika Raises an 8.4M EUR Series-A Round

Retrieved on: 
Thursday, September 26, 2019
Medicine, Clinical medicine, Neurotechnology, Neurosurgical procedures, Electrotherapy, Medical devices, Deep brain stimulation, Tourette syndrome, DBS, Policlinico of Milan, Brain stimulation

MILAN, Sept.26, 2019 /PRNewswire/ --Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round.

Key Points: 
  • MILAN, Sept.26, 2019 /PRNewswire/ --Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round.
  • Newronika has developed a closed-loop system for Deep Brain Stimulation (DBS), the first of its kind.
  • The round will allow Newronika to complete its first in man clinical study, get CE-Mark and obtain FDA IDE.
  • "This round puts Newronika straight into the global competition for DBS technology and turns our company into a player to be reckoned with," commented Alain Garcinuo, Newronika's CFO.